Castle Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary

Castle Biosciences

04/08/2025 22:02

Castle Biosciences Inc CSTL.OQ reported quarterly adjusted earnings of 15 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 31 cents.  The mean expectation of nine analysts for the quarter was for a loss of 52 cents per share. Wall Street expected results to range from -66 cents to -36 cents per share.

Revenue fell 0.9% to $86.19 million from a year ago; analysts expected $71.41 million.

Castle Biosciences Inc's reported EPS for the quarter was 15 cents​.

The company reported quarterly net income of $4.52 million.

Castle Biosciences Inc shares had fallen by 28.3% this quarter and lost 45.0% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 10% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is  "buy."

Wall Street's median 12-month price target for Castle Biosciences Inc is $36.00, about 59.3% above its last closing price of $14.65

This summary was machine generated from LSEG data August 4 at 09:02 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.52
0.15
Beat
Mar. 31 2025
-0.07
-0.20
Missed
Dec. 31 2024
0.05
0.33
Beat
Sep. 30 2024
-0.06
0.08
Beat